Episode 921
TWiV 921: COVID-19 clinical update #124 with Dr. Daniel Griffin
July 23, 202235m 13s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In COVID-19 clinical update #124, Dr. Griffin discusses the results of a variant vaccine booster trial, the neutralization of variant sub-lineages by Novavax, the CDC's recommendation of Novavax's COVID-19 vaccine in adults, Paxlovid in patients who are immunocompromised and hospitalized, and inhaled fluticasone for outpatient treatment.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Variant vaccine boosters trial (medRxiv)
- Novavax triggers neutralization of variant sub-lineages (bioRxiv)
- CDC recommends Novavax (CDC)
- Paxlovid in patients who are immunocompromised and hospitalized (The Lancet)
- Inhaled Fluticasone for outpatient treatment (medRxiv)
- PAXLOVID patient eligibility screening checklist (FDA)
- Remdesivir fact sheet for providers (Veklury)
- Bebtelovimab fact sheet for providers (FDA)
- Contribute to FIMRC fundraiser at PWB
- Dr. Griffin's treatment guide (pdf)
- Letters read on TWiV 921
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]